DnB Asset Management AS Buys 2,865 Shares of Moderna, Inc. (NASDAQ:MRNA)

DnB Asset Management AS grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 5.2% in the fourth quarter, HoldingsChannel reports. The fund owned 57,755 shares of the company’s stock after acquiring an additional 2,865 shares during the period. DnB Asset Management AS’s holdings in Moderna were worth $2,401,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MRNA. Wilmington Savings Fund Society FSB increased its stake in shares of Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock valued at $33,000 after buying an additional 587 shares during the period. Compass Planning Associates Inc bought a new position in Moderna in the fourth quarter valued at about $37,000. Venturi Wealth Management LLC increased its position in Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares during the period. Crowley Wealth Management Inc. bought a new stake in Moderna during the 4th quarter worth about $41,000. Finally, MassMutual Private Wealth & Trust FSB lifted its position in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Bank of America dropped their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Berenberg Bank increased their price target on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. The Goldman Sachs Group lowered Moderna from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $99.00 to $51.00 in a research report on Wednesday, January 29th. Evercore ISI set a $50.00 price objective on Moderna in a report on Friday, February 14th. Finally, Leerink Partners reduced their target price on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $59.00.

Moderna Trading Down 4.2 %

Shares of MRNA stock opened at $27.16 on Wednesday. The firm’s fifty day moving average price is $34.43 and its two-hundred day moving average price is $43.55. Moderna, Inc. has a 1 year low of $26.80 and a 1 year high of $170.47. The firm has a market capitalization of $10.50 billion, a P/E ratio of -2.93 and a beta of 1.86.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.